C4 Therapeutics, Inc. Logo

C4 Therapeutics, Inc.

Developing protein degrader medicines to treat cancer and other serious diseases.

CCCC | US

Overview

Corporate Details

ISIN(s):
US12529R1077
LEI:
Country:
United States of America
Address:
490 ARSENAL WAY, 2472 WATERTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on developing a new class of medicines through targeted protein degradation (TPD). The company's approach utilizes the body's natural protein disposal mechanisms to selectively eliminate disease-causing proteins. C4T leverages its proprietary TORPEDO® (Target Oriented Protein Degrader Optimizer) platform to design and advance a pipeline of small-molecule drug candidates aimed at treating cancer and other serious diseases. Its portfolio includes clinical programs such as Cemsidomide (CFT7455), CFT8919, and CFT1946.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all C4 Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for C4 Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for C4 Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
FATE THERAPEUTICS INC Logo
Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.
United States of America FATE
FENNEC PHARMACEUTICALS INC. Logo
Prevents chemotherapy-induced hearing loss in children with its sole product, PEDMARK®.
United States of America FENC
FibroBiologics, Inc. Logo
Clinical-stage biotech developing fibroblast cell therapies for chronic diseases.
United States of America FBLG
FIBROGEN INC Logo
Biopharma developing first-in-class therapies for cancer, anemia, and serious conditions.
United States of America FGEN
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Flora Growth Corp. Logo
A diversified firm in pharma distribution, plant-based wellness, and digital assets.
United States of America FLGC
Foghorn Therapeutics Inc. Logo
Pioneering medicines targeting the chromatin regulatory system to treat genetically defined cancers.
United States of America FHTX
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Fortress Biotech, Inc. Logo
Acquires, develops, and commercializes drugs for oncology, gene therapy, and rare diseases.
United States of America FBIO
FRACTYL HEALTH, INC. Logo
Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.
United States of America GUTS

Talk to a Data Expert

Have a question? We'll get back to you promptly.